Alignment Healthcare, Inc. (ALHC) company profile
Close on Nov 18, 2026Market cap $1.41BP/E 61.1Yield –
About Alignment Healthcare
Hospital & Medical Service Plans, SIC 6324
Alignment Healthcare, Inc. provides healthcare services and Medicare Advantage plans to senior citizens in the United States. The company operates through a single segment, partnering directly with the Centers for Medicare and Medicaid Services to coordinate and manage member healthcare. Its primary offerings consist of Medicare Advantage health maintenance organization and preferred provider organization plans. These plans cover inpatient and outpatient care, physician services, prescription drug benefits, and supplemental options such as dental and vision care. The company delivers proactive clinical care, manages chronic health conditions, and assists members in their communities, in their homes, and online. Its customer base consists of Medicare-eligible seniors who enroll in its private health plans.
The company is headquartered in Orange, California. As of December 31, 2025, Alignment Healthcare serves approximately 236,300 members. For the 2025 plan year, the organization provides coverage across 45 markets in five states, including 22 markets in California, 16 in North Carolina, three in Arizona, two in Nevada, and two in Texas.
Summary of the business section of Alignment Healthcare's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Alignment Healthcare, Inc.
- Founded
- 2013
- Headquarters
- Orange, CA
- Address
- 1100 W. Town And Country Road, Suite 1600 92868
- Phone
- (844) 310-2247
- Website
- alignmenthealthcare.com
- Employees
- 1,849, Dec 31, 2025
- Industry
- Hospital & Medical Service Plans
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Costa Mesa, California
Stock & identifiers
- Ticker
- ALHC
- Exchange
- Nasdaq
- IPO date
- Mar 29, 2021
- Shares outstanding
- 209M, Oct 26, 2026
- Public float
- $2.06B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1832466
- CUSIP
- 01625V104
- ISIN
- US01625V1044
- FIGI
- BBG00ZJ0DSR6
- Share class FIGI
- BBG00ZJ0DSS5
- EIN
- 46-5596242
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joseph S. Konowiecki | EVP, Corporate Affairs, Director | 1,075,375 |
| John E. Kao | Chief Executive Officer, Director | 1,814,239 |
| Hyong Kim | Chief Medical Officer | 299,271 |
| Dawn Christine Maroney | President | 794,606 |
| Shane J. Hochradel | Chief Operations Officer | 87,719 |
| Mark D. Kent | President - MSO | 102,567 |
| James M. Head | Chief Financial Officer | 173,495 |
| Christopher J. Joyce | Chief Legal and Admin. Officer | 305,451 |
| Sebastian Burzacchi | COO - Mgmt Services Org | 258,630 |
| Robert L. Scavo | Chief Information Officer | 487,685 |
| Andreas P. Wagner | Chief Human Resources Officer | 148,628 |
| Adnan R. Mansour | Chief Digital Officer | 48,456 |
| Hakan Kardes | Chief Experience Officer | 678,987 |
| Robert Thomas Freeman | Chief Financial Officer | 1,557,348 |
| Mark B. McClellan | Director | 370,531 |
| Yon Jorden | Director | 105,830 |
| Nicholas Robbert Vorhoff | Director | 173,408 |
| Jacqueline B. Kosecoff | Director | 303,963 |
| Margaret M. McCarthy | Director | 144,441 |
| Jody L. Bilney | Director | 129,267 |
| David C. Hodgson | Director | 173,408 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $11.28M | $52.29M | $3.57M | $114 | $101 |
| FY2024 | $6.37M | $25.24M | $2.72M | $65 | $82 |
| FY2023 | $14.30M | -$2.67M | $4.76M | $50 | $83 |
| FY2022 | $34.07M | $25.81M | $7.33M | $68 | $78 |
| FY2021 | $46.00M | $37.30M | $10.89M | $81 | $98 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| John Kao Chief Executive Officer | $833.65K | $8.50M | $1.94M | $420 | $11.28M | +77% |
| Dawn Maroney President | $676.92K | $3.70M | $1.05M | $14.42K | $5.44M | +77% |
| James M. Head Chief Financial Officer | $394.62K | $2.50M | $429.30K | $1.91K | $3.33M | – |
| Thomas Freeman Former Chief Financial Officer | $501.92K | $1.90M | $476.67K | $8.22K | $2.89M | +1% |
| Hyong (Ken) Kim, M.D. Chief Medical Officer | $560.00K | $1.80M | $754.59K | $14.42K | $3.13M | +26% |
| Christopher Joyce Chief Legal & Administrative Officer | $525.00K | $1.75M | $760.44K | $14.00K | $3.05M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 29, 2021
- Offer price
- $18.00
- Securities offered
- 27,200,000
- Gross proceeds
- $489.60M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Sep 25, 2021
“The initial public offering price is $18.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 1,849 full-time employees in addition to seasonal employees who assist with the Medicare AEP.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 29, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 26, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?